A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 2265-2275

  Chen, Jingde ^a   Jiang, Hong ^a   Wu, Yin ^a   Li, Yandong ^a   Gao, Yong ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Biodistribution; Drug delivery; Modified liposomes; Pharmacokinetics; Target

Indexed keywords

CARBOPLATIN; GLYCYRRHETINIC ACID; LIPOSOME; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL DEATH; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DISPERSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; EPITHELIUM CELL; FILM; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; SUSTAINED DRUG RELEASE; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; ELECTROCHEMISTRY; LIVER NEOPLASMS; MOUSE; PROCEDURES; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ELECTROCHEMISTRY; GLYCYRRHETINIC ACID; LIPOSOMES; LIVER; LIVER NEOPLASMS; MICE; ORGANOPLATINUM COMPOUNDS; PARTICLE SIZE; RATS; TISSUE DISTRIBUTION;

EID: 84929191259     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S81722     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin. 2005;55(2):74–108.
2. Khan AS, Fowler KJ, Chapman WC. Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol. 2014;20(41):15007–15017.
3. Sherman M, Colombo M. Hepatocellular carcinoma screening and diagnosis. Semin Liver Dis. 2014;34(4):389–397.
4. O’Suilleabhain CB, Poon RT, Yong JL, Ooi GC, Tso WK, Fan ST. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg. 2003;90(3):325–331.
5. Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol. 2004;5(7):409–418.
6. Bonetti A, Giuliani J, Muggia F. Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer. Anticancer Res. 2014;34(1):423–434.
7. Thota R, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology (Williston Park). 2014;28(1):70–74.
8. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer. 2007;109(7):1384–1390.
9. Yen Y, Lim DW, Chung V, et al. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am J Clin Oncol. 2008;31(4):317–322.
10. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One. 2011;6(4):e18469.
11. Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A. 2012;109(17):6704–6709.
12. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49–60.
13. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–160.
14. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
15. Yang C, Liu HZ, Lu WD, Fu ZX. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma. Oncol Rep. 2011;25(6):1621–1628.
16. Abu-Lila A, Suzuki T, Doi Y, Ishida T, Kiwada H. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model. J Control Release. 2009;134(1):18–25.
17. Negishi M, Irie A, Nagata N, Ichikawa A. Specific binding of glycyrrhetinic acid to the rat liver membrane. Biochim Biophys Acta. 1991;1066(1):77–82.
18. Shiki Y, Shirai K, Saito Y, Yoshida S, Mori Y, Wakashin M. Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrane antibody. J Gastroenterol Hepatol. 1992;7(1):12–16.
19. Il’icheva TN, Proniaeva TR, Smetannikov AA, Pokrovskiĭ AG. [Content of progesterone, glucocorticoid and glycyrrhizic acid receptors in normal and tumoral human breast tissue]. Vopr Onkol. 1998;44(4):390–394. Russian.
20. Tian Q, Zhang CN, Wang XH, et al. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials. 2010;31(17):4748–4756.
21. Huang W, Wang W, Wang P, et al. Glycyrrhetinic acid-functionalized degradable micelles as liver-targeted drug carrier. J Mater Sci Mater Med. 2011;22(4):853–863.
22. Mao SJ, Bi YQ, Jin H, Wei DP, He R, Hou SX. Preparation, characterization and uptake by primary cultured rat hepatocytes of liposomes surface-modified with glycyrrhetinic acid. Pharmazie. 2007;62(8):614–619.
23. He ZY, Zheng X, Wu XH, et al. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery. Int J Pharm. 2010;397(1–2):147–154.
24. Franzen U, Nguyen TT, Vermehren C, Gammelgaard B, Ostergaard J. Characterization of a liposome-based formulation of oxaliplatin using capillary electrophoresis: encapsulation and leakage. J Pharm Biomed Anal. 2011;55(1):16–22.
25. Li J, Xu H, Ke X, Tian J. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid. J Drug Target. 2012;20(5):467–473.
26. Kim SY, Lee YM. Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(epsilon-caprolactone) as novel anticancer drug carriers. Biomaterials. 2001;22(13):1697–1704.
27. International Conference on Harmonisation; Stability Data Package for Registration Applications in Climatic Zones III and IV; Stability Testing of New Drug Substances and Products; availability. Notice. Food and Drug Administration, HHS. Fed Regist. 2003;68(225):65717–65718.
28. Chen C, Han D, Cai C, Tang X. An overview of liposome lyophilization and its future potential. J Control Release. 2010;142(3):299–311.
29. Service RF. Nanomaterials show signs of toxicity. Science. 2003;300(5617):243.
30. Gumpricht E, Dahl R, Devereaux MW, Sokol RJ. Licorice compounds glycyrrhizin and 18beta-glycyrrhetinic acid are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes. J Biol Chem. 2005;280(11):10556–10563.
31. Cheng M, Xu H, Wang Y, et al. Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells. Drug Des Devel Ther. 2013;7:1287–1299.